Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

The combination therapy was effective and well-tolerated, especially in young patients.

Erlotinib can cause persistent excessive hair growth.

A wearable device using NIR light may help treat hair loss non-invasively.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Exosome-based therapies in dermatology show promise but face challenges in standardization, regulation, and safety.

The eucalyptus oil system improved skin delivery of hormones, but safety concerns remain.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Extracellular vesicles are important for disease treatment and monitoring.

STS01 1% effectively promotes hair regrowth with minimal side effects.

Advancements in skin treatment and wound healing include promising gene therapy, 3D skin models, and potential new therapies.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

A new engineered treatment shows promise in curing heart fibrosis.

Essential oils can improve health but must be used safely under professional guidance.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

GC10/DOX hydrogel shows promise as an effective thyroid cancer treatment.

Aptamers can improve wound healing and promote hair growth.